ALPCO to Highlight Assay Qualification Program at the AACCs 69th Annual

Scientific Meeting and Clinical Lab Expo

ALPCO announced it will feature a variety of products supported by its assay qualification program
at the AACCs 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3,
2017. Among these products is the Easy Stool Extraction Device and a Therapeutic Drug
Monitoring ELISA portfolio.

Salem, NH, July 25, 2017 --(PR.com)-- ALPCO, a leading producer of research and clinical
immunoassays, announced it will feature a variety of products supported by its assay qualification
program at the AACC's 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3,
2017. Among these products is the Easy Stool Extraction Device which is compatible with a number of
gastroenterology ELISA testing panels. ALPCO's Therapeutic Drug Monitoring ELISA portfolio will
also be highlighted at the meeting.

The assay qualification program has been designed to assist labs in offsetting the financial and
operational hurdles that can arise when onboarding new tests. As part of the program, customers are
provided with on-site support from a Field Applications Scientist to assist with qualification parameters.
Customers are also supported with evaluation materials, training, documentation, and reference guides
where appropriate.

The Easy Stool Extraction Device is an FDA Class I Exempt sample collection device that can be used
across a comprehensive gastroenterology ELISA testing panel. The device allows lab technicians to
replace manual weighing with one simple extraction step, therefore saving time and improving lab
efficiency. The Easy Stool Extraction Device is compatible with ALPCO's testing panels to investigate
inflammatory bowel disease, exocrine pancreatic function, celiac disease, and colorectal cancer.

ALPCO will also feature its Therapeutic Drug Monitoring ELISA portfolio to investigate inflammatory
bowel diseases at the AACC's 69th Annual Scientific Meeting and Clinical Lab Expo. The TDM ELISA
portfolio includes assays to measure both drug and anti-drug antibody levels of TNF-alpha blockers
adalimumab, infliximab, golimumab, and vedolizumab.

Our assay qualification program was developed to help institutions save time and and ease the burden of
onboarding new tests, said ALPCO President Sean Conley. Ultimately, our aim is to allow for savings
that will result in lower overall healthcare costs in the industry.

Visit ALPCO in booth 5307 at the AACC's 69th Annual Scientific Meeting and Clinical Lab Expo to
learn more.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of
immunoassay-based products for the North American life science markets. The company has since grown
into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO

Page 1/3
PR.com Press Release Distribution Terms of Use
offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools
for advancing research and improving quality of care.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
ALPCO
Bethany Bell, PhD
1-800-592-5726
Contact via Email
www.alpco.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/724246

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use